Substance
ID:718
Names and Identifiers
Brand Name
GabrenGabrene
IUPAC name
4-{[(4-chlorophenyl)[(1E)-3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene]methyl]amino}butanamide
Synonyms
ProgabideHalogabideProgabidum [INN-Latin]Progabide [Usan:Ban:Inn]Progabida [INN-Spanish]
IUPAC Traditional name
gabren
Properties
Physical Property
Solubility
70.9 mg/L
Hydrophobicity(logP)
2.6
Molecule Details
Drug Groups
approved
Description
Progabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors. Progabide has been investigated for many diseases besides epilepsy, including Parkinson's disease, schizophrenia, clinical depression and anxiety disorder with varying success.
Indication
Indicated for the treatment of epilepsy.
Pharmacology
Progabide, a fatty acid derivative, is a GABA receptor agonist used to treat the symptoms of epilepsy.
Affected Organisms
Humans and other mammals
Biotransformation
Hepatic
Absorption
Well absorbed with a bioavailability of 60%
Half Life
4 hours
Protein Binding
95%
References
•
Bartholini G, Scatton B, Zivkovic B, Lloyd KG: GABA receptor agonists and extrapyramidal motor function: therapeutic implications for Parkinson's disease. Adv Neurol. 1987;45:79-83.
[Pubmed]
External Links
Molecular Spectra
No Data Available
Click here to submit data
References
• Bartholini G, Scatton B, Zivkovic B, Lloyd KG: GABA receptor agonists and extrapyramidal motor function: therapeutic implications for Parkinson's disease. Adv Neurol. 1987;45:79-83. Pubmed